{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:25:18Z","timestamp":1773332718990,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,9]],"date-time":"2008-04-09T00:00:00Z","timestamp":1207699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00280-008-0746-2","type":"journal-article","created":{"date-parts":[[2008,4,8]],"date-time":"2008-04-08T11:15:26Z","timestamp":1207653326000},"page":"363-370","source":"Crossref","is-referenced-by-count":66,"title":["A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma"],"prefix":"10.1007","volume":"63","author":[{"given":"L. C.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"A. B.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Mena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Picus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Ajani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. R. J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,9]]},"reference":[{"key":"746_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0895-4356(02)00534-6","volume":"56","author":"JR Kelley","year":"2003","unstructured":"Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1\u20139","journal-title":"J Clin Epidemiol"},{"key":"746_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.265.10.1287","volume":"265","author":"WJ Blot","year":"1991","unstructured":"Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287\u20131289","journal-title":"JAMA"},{"key":"746_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37\u201341","journal-title":"Cancer"},{"key":"746_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrhonen","year":"1995","unstructured":"Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587\u2013591","journal-title":"Br J Cancer"},{"key":"746_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163\u2013168","journal-title":"Ann Oncol"},{"key":"746_CR6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a058932","volume":"5","author":"M Findlay","year":"1994","unstructured":"Findlay M, Cunningham D, Norman A et al (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609\u2013616","journal-title":"Ann Oncol"},{"key":"746_CR7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","volume":"15","author":"A Webb","year":"1997","unstructured":"Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261\u2013267","journal-title":"J Clin Oncol"},{"key":"746_CR8","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/annonc\/mdh422","volume":"15","author":"SS Wohrer","year":"2004","unstructured":"Wohrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15:1585\u20131595","journal-title":"Ann Oncol"},{"key":"746_CR9","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991\u20134997","journal-title":"J Clin Oncol"},{"key":"746_CR10","first-page":"1033","volume":"21","author":"K Futatsuki","year":"1994","unstructured":"Futatsuki K, Wakui A, Nakao I et al (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 21:1033\u20131038","journal-title":"Gan To Kagaku Ryoho"},{"key":"746_CR11","first-page":"26","volume":"14","author":"PC Enzinger","year":"2000","unstructured":"Enzinger PC, Ilson DH (2000) Irinotecan in esophageal cancer. Oncology 14:26\u201330","journal-title":"Oncology"},{"key":"746_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/A:1005899720463","volume":"15","author":"JK Benedetti","year":"1997","unstructured":"Benedetti JK, Burris HA 3rd, Balcerzak SP, Macdonald JS (1997) Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group Study. Invest New Drugs 15:261\u2013264","journal-title":"Invest New Drugs"},{"key":"746_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/00000421-199712000-00018","volume":"20","author":"LB Saltz","year":"1997","unstructured":"Saltz LB, Schwartz GK, Ilson DH et al (1997) A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. Am J Clin Oncol 20:621\u2013625","journal-title":"Am J Clin Oncol"},{"key":"746_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v17.i2.20","volume":"17","author":"RB Greenwald","year":"2000","unstructured":"Greenwald RB, Conover CD, Choe YH (2000) Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit Rev Ther Drug Carrier Syst 17:101\u2013161","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"746_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1021\/bc000064z","volume":"12","author":"S Lee","year":"2001","unstructured":"Lee S, Greenwald RB, McGuire J et al (2001) Drug delivery systems employing 1, 6-elimination: releasable poly(ethylene glycol) conjugates of proteins. Bioconjug Chem 12:163\u2013169","journal-title":"Bioconjug Chem"},{"key":"746_CR16","first-page":"3361","volume":"17","author":"CD Conover","year":"1997","unstructured":"Conover CD, Pendri A, Lee C et al (1997) Camptothecin delivery systems: the antitumor activity of a camptothecin-20-0-polyethylene glycol ester transport form. Anticancer Res 17:3361\u20133368","journal-title":"Anticancer Res"},{"key":"746_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s002800050837","volume":"42","author":"CD Conover","year":"1998","unstructured":"Conover CD, Greenwald RB, Pendri A et al (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol 42:407\u2013414","journal-title":"Cancer Chemother Pharmacol"},{"key":"746_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.2003.03.143","volume":"21","author":"EK Rowinsky","year":"2003","unstructured":"Rowinsky EK, Rizzo J, Ochoa L et al (2003) A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3\u00a0weeks in patients with advanced solid malignancies. J Clin Oncol 21:148\u2013157","journal-title":"J Clin Oncol"},{"key":"746_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143\u2013151","journal-title":"Biometrics"},{"key":"746_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"746_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"746_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"746_CR23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579","journal-title":"J Clin Oncol"},{"key":"746_CR24","first-page":"625","volume-title":"Textbook of biochemistry with clinical correlations","author":"S Aktipis","year":"1986","unstructured":"Aktipis S (1986) DNA: the replication process and repair. In: Devleri TM (ed) Textbook of biochemistry with clinical correlations. Wiley, New York, p 625"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1021\/ja00968a057","volume":"88","author":"ME Wall","year":"1966","unstructured":"Wall ME, Wani MC, Cook CE et al (1966) Plant antitumor agents 1: the isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumor inhibitor for Camptotheca accuminata. J Am Chem Soc 88:3888\u20133890","journal-title":"J Am Chem Soc"},{"key":"746_CR26","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","volume":"260","author":"YH Hsiang","year":"1985","unstructured":"Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873\u201314878","journal-title":"J Biol Chem"},{"key":"746_CR27","first-page":"1722","volume":"48","author":"YH Hsiang","year":"1988","unstructured":"Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722\u20131726","journal-title":"Cancer Res"},{"key":"746_CR28","first-page":"461","volume":"54","author":"JA Gottlieb","year":"1970","unstructured":"Gottlieb JA, Guarino AM, Call JB et al (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461\u2013470","journal-title":"Cancer Chemother Rep"},{"key":"746_CR29","first-page":"175","volume":"57","author":"PJ Creaven","year":"1973","unstructured":"Creaven PJ, Allen LM (1973) Renal clearance of camptothecin (NSC-100880): effect of urine volume. Cancer Chemother Rep 57:175\u2013184","journal-title":"Cancer Chemother Rep"},{"key":"746_CR30","first-page":"641","volume":"8","author":"R Garcia-Carbonero","year":"2002","unstructured":"Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641\u2013661","journal-title":"Clin Cancer Res"},{"key":"746_CR31","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(03)13780-4","volume":"361","author":"JF Pizzolato","year":"2003","unstructured":"Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235\u20132242","journal-title":"Lancet"},{"key":"746_CR32","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1007\/s10620-005-3038-2","volume":"50","author":"PC Enzinger","year":"2005","unstructured":"Enzinger PC, Kulke MH, Clark JW et al (2005) A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 50:2218\u20132223","journal-title":"Dig Dis Sci"},{"key":"746_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.bjc.6601226","volume":"89","author":"CH Kohne","year":"2003","unstructured":"Kohne CH, Catane R, Klein B et al (2003) Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 89:997\u20131001","journal-title":"Br J Cancer"},{"key":"746_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10637-005-2907-z","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Takimoto C, Becerra CR et al (2005) A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs 23:479\u2013484","journal-title":"Invest New Drugs"},{"key":"746_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1023\/B:DRUG.0000026259.28395.c2","volume":"22","author":"HL Kindler","year":"2004","unstructured":"Kindler HL, Avadhani A, Wade-Oliver K et al (2004) 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: a phase II trial of the University of Chicago phase II consortium. Invest New Drugs 22:323\u2013327","journal-title":"Invest New Drugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0746-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0746-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0746-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T13:54:31Z","timestamp":1631022871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0746-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,9]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0746-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,9]]}}}